Multiple endocrine neoplasia type 2 epidemiology and demographics
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 epidemiology and demographics |
|
FDA on Multiple endocrine neoplasia type 2 epidemiology and demographics |
|
CDC on Multiple endocrine neoplasia type 2 epidemiology and demographics |
|
Multiple endocrine neoplasia type 2 epidemiology and demographics in the news |
|
Blogs on Multiple endocrine neoplasia type 2 epidemiology and demographics |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
The prevalence of multiple endocrine neoplasia type 2 is approximately 2.5 per 100,000 individuals worldwide. Multiple endocrine neoplasia type 2B manifests in early infancy while multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma manifest in adulthood.
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of multiple endocrine neoplasia type 2 is 2.5 per 100,000 individuals in 2010.[1]
- Multiple endocrine neoplasia type 2 has been reported in approximately 500 to 1000 families worldwide.[2]
- 70-80% of all multiple endocrine neoplasia type 2 cases are multiple endocrine neoplasia type 2A.
Incidence
- In the United States, an estimated 468 cases of multiple endocrine neoplasia type 2-related medullary thyroid cancer are diagnosed per year.[3]
Age
- Multiple endocrine neoplasia type 2 can be found in any age group.
- Multiple endocrine neoplasia type 2B manifests in early infancy while multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma manifest in adulthood.[4]
Gender
- The prevalence and incidence of multiple endocrine neoplasia type 2 do not vary by gender.[5]
Race
- The prevalence of multiple endocrine neoplasia type 2 does not vary by race.[6]
Developed Countries
- In United States the prevalence of multiple endocrine neoplasia type 2 is 2 - 4 per 100,000 individuals.[7]
References
- ↑ Wells, Samuel A.; Pacini, Furio; Robinson, Bruce G.; Santoro, Massimo (2013). "Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update". The Journal of Clinical Endocrinology & Metabolism. 98 (8): 3149–3164. doi:10.1210/jc.2013-1204. ISSN 0021-972X.
- ↑ Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015
- ↑ Medullary thyroid genetics. National cancer institute (30.10.2015). http://www.cancer.gov/types/thyroid/hp/medullary-thyroid-genetics-pdq#cit/section_1.7 Accessed on October, 30, 2015
- ↑ Wells, Samuel A.; Pacini, Furio; Robinson, Bruce G.; Santoro, Massimo (2013). "Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update". The Journal of Clinical Endocrinology & Metabolism. 98 (8): 3149–3164. doi:10.1210/jc.2013-1204. ISSN 0021-972X.
- ↑ Romei, C.; Pardi, E.; Cetani, F.; Elisei, R. (2012). "Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2". Journal of Oncology. 2012: 1–15. doi:10.1155/2012/705036. ISSN 1687-8450.
- ↑ Romei, C.; Pardi, E.; Cetani, F.; Elisei, R. (2012). "Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2". Journal of Oncology. 2012: 1–15. doi:10.1155/2012/705036. ISSN 1687-8450.
- ↑ Norton, Jeffrey A.; Krampitz, Geoffrey; Jensen, Robert T. (2015). "Multiple Endocrine Neoplasia". Surgical Oncology Clinics of North America. 24 (4): 795–832. doi:10.1016/j.soc.2015.06.008. ISSN 1055-3207.
]]